Icon

BELEODAQ (nda206256)- (500MG/VIAL)

BELINOSTAT ACROTECH BIOPHARMA
500MG/VIAL
Yes No
2027-Oct-27 2019-Jul-03
2021-Jul-03 None
None No
Beleodaq is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response.
0 0 0
Total Other Developers 2
Drugs with Suitability No
500MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.